The Role of Alfuzosin in the Treatment of Benign Prostate Hyperplasia and Acute Urinary Retention

Abstract

α-adrenergic receptor antagonists can be considered as a first-line treatment in patients with symptomatic benign prostate hyperplasia. Alfuzosin is a clinically uroselective α-adrenergic receptor antagonist and is used in the treatment of this disorder. This article will report on the pharmacodynamic data and efficacy results from up-to-date clinical trials of alfuzosin. It will also examine the role of this drug in the treatment of acute urinary retention.